JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 1
DOI:10.33266/1024-6177-2025-70-1-109-114
V.I. Chernov1, 2, 3, A.N. Rybina1, R.V. Zelchan1, 2, A.A. Medvedeva1, O.D. Bragina1, 2,
N.A. Lushnikova1, E.A. Usynin1, A. Abouzayed4, S.S. Rinne4, J. Sörensen5,
V.М. Tolmachev2, 6, A.М. Orlova2, 4, 7
The Gastrin-Releasing Peptide Receptor Antagonist [99MTc]Tc-Rm26 is a Novel Radiopharmaceutical for Prostate Cancer Imaging
1 Scientific Research Institute of Oncology, Tomsk National Research Medical Center, Tomsk, Russia
2 Oncoteranostics Research Center, Scientific Research School of Chemistry and Applied Biomedical
Sciences, Polytechnic University, Tomsk, Russia
3 National Research Center ‟Kurchatov Institute”, Moscow, Russia
4 Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
5 Department of Surgical Sciences, Nuclear Medicine & PET, Uppsala University, Uppsala, Sweden
6 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
7 Science for Life Laboratory, Uppsala University, Uppsala, Sweden
Contact person: V.I. Chernov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Gastrin releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PC). Currently, radiopharmaceuticals (RP) for visualization of GPRP based on bombesin antagonists are developed. The aim of the present work was to conduct a phase I clinical trial of the GRPR antagonist [99mTc]Tc-RM26 and to study the possibility of its use for PC SPECT imaging. Thirteen patients diagnosed with PC were included in the study. Patients received [99mTc]Tc-RM26 intravenous bolus at a dose of 640±165 MBq (40 μg/injection). Six patients underwent whole-body planar imaging and SPECT/CT at 2, 4, 6, and 24 h after injection. Seven patients had SPECT/CT alone performed 2 h after RFP injection. The study showed that a single intravenous injection of [99mTc]Tc-RM26 is safe and well tolerated. Critical organs for RFP are the gallbladder, small intestine, upper colon and kidney. The dose burden per patient associated with the administration of [99mTc]Tc-RM26 RFP is 3–6 mSv per study. The studied RP allows to visualize primary prostate malignant tumors, as well as its metastases to lymph nodes and bones. It is reasonable to conduct further clinical studies of [99mTc]Tc-RM26 to evaluate the sensitivity and specificity of SPECT/CT with this RP for diagnostics and staging of prostate cancer.
Keywords: prostate cancer, gastrin-releasing peptide receptor antagonist, [99mTc]Tc-RM26, SPECT
For citation: Chernov VI, Rybina AN, Zelchan RV, Medvedeva AA, Bragina OD, Lushnikova NA, Usynin EA, Abouzayed A, Rinne SS, Sörensen J, Tolmachev VМ, Orlova AМ. The Gastrin-Releasing Peptide Receptor Antagonist [99MTc]Tc-Rm26 is a Novel Radiopharmaceutical for Prostate Cancer Imaging. Medical Radiology and Radiation Safety. 2025;70(1):109–114. (In Russian). DOI:10.33266/1024-6177-2025-70-1-109-114
References
1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249.
2. Состояние онкологической помощи населению России в 2022 году / Под ред. А.Д.Каприна, В.В.Старинского, А.О.Шахзадовой. М.: МНИОИ им. П.А.Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с. [Sostoyaniye Onkologicheskoy Pomoshchi Naseleniyu Rossii v 2022 Godu = The State of Oncological Care for the Population of Russia in 2022. Ed. A.D.Kaprin, V.V.Starinskiy, A.O.Shakhzadova. Moscow Publ., 2022. 239 p. (In Russ.)].
3. Miller K.D., Nogueira L., Devasia T., Mariotto A.B., Yabroff K.R., Jemal A., Kramer J., Siegel R.L. Cancer Treatment and Survivorship Statistics. CA Cancer J Clin. 2022;72:409-436. doi: 10.3322/caac.21731.
4. Von Eyben F.E., Picchio M., von Eyben R., Rhee H., Bauman G. 68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. Focus. 2018;4:686–693.
5. Ananias H.J., van den Heuvel M.С., Helfrich W., de Jong I.J. Expression of the Gastrin-Releasing Peptide Receptor, the Prostate Stem Cell Antigen and the Prostate-Specific Membrane Antigen in Lymph Node and Bone Metastases of Prostate Cancer. Prostate. 2009;69:1101–1108.
6. Beer M., Montani M., Gerhardt J., Wild P.J., Hany T.F., Hermanns T., Müntener M., Kristiansen G. Profiling Gastrin-Releasing Peptide Receptor in Prostate Tissues: Clinical Implications and Molecular Correlates. Prostate. 2012;72:318-325.
7. Cornelio D.B., Roesler R., Schwartsmann G. Gastrin-Releasing Peptide Receptor as a Molecular Target in Experimental Anticancer Therapy. Ann Oncol. 2007;18;1457-1466. doi: 10.1093/annonc/mdm058.
8. Dalm S.U., Martens J.W., Sieuwerts A.M., van Deurzen C.H., Koelewijn S.J., de Blois E., Maina T., Nock B.A., Brunel L., Fehrentz J.-A., Martinez J., de Jong M., Melis M. In vitro and in vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. J Nucl Med. 2015;56:752-757. doi: 10.2967/jnumed.114.153023.
9. Morgat C., MacGrogan G., Brouste V., Vélasco V., Sévenet N., Bonnefoi H., Fernandez P., Debled M., Hindié E. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic. Biologic. and Clinical Parameters: a Study of 1.432 Primary Tumors. J Nucl Med. 2017;58:1401-1407. doi: 10.2967/jnumed.116.188011.
10. Ceci F., Castellucci P., Polverari G., Iagaru A. Clinical Application of Fluciclovine PET. Choline PET and Gastrin-Releasing Polypeptide Receptor (Bombesin) Targeting PET in Prostate Cancer. Curr Opin Urol. 2020;30:641-648. doi: 10.1097/MOU.0000000000000794.
11. Bodei L., Ferrari M., Nunn A., Llull J., Cremonesi M., Martano L., Laurora G., Scardino E., Tiberini S., Bufi G., Eato de Cobelli O., Paganelli G. 177Lu-AMBA Bombesin Analogue in Hormone Refractory Prostate Cancer Patients: a Phase I Escalation Study with Single-Cycle Administrations [Abstract]. Eur J Nucl Med Mol Imaging. 2007;34;2:221.
12. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L., Halmos G. Hypothalamic Hormones and Cancer. Front Neuroendocrinol. 2001;22:248–291.
13. Millar J.B.; Rozengurt E. Chronic Desensitization to Bombesin by Progressive Down-Regulation of Bombesin Receptors in Swiss 3T3 cells. Distinction from Acute Desensitization. J Biol Chem. 1990;265:12052–12058.
14. Schwartsmann G., DiLeone L.P., Horowitz M., Schunemann D., Cancella A., Pereira A.S., Richter M., Souza F., da Rocha A.B., Souza F.H., Pohlmann P., De Nucci G. A Phase I Trial of the Bombesin/Gastrin-Releasing Peptide (BN/GRP) Antagonist RC3095 in Patients with Advanced Solid Malignancies. Invest New Drugs. 2006;24:403–412.
15. Mansi R., Nock B.A., Dalm S.U., Busstra M.B., van Weerden W.M., Maina T. Radiolabeled Bombesin Analogs. Cancers (Basel). 2021;13:5766. doi: 10.3390/cancers13225766.
16. Nock B.A., Kaloudi A., Kanellopoulos P., Janota B., Bromińska B., Iżycki D., Mikołajczak R., Czepczynski R., Maina T. [99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: from Preclinical Evaluation to the First Clinical Outcomes. Cancers (Basel). 2021;13:5093. doi: 10.3390/cancers13205093.
17. Abouzayed A., Rinne S.S., Sabahnoo H., Sörensen J., Chernov V., Tolmachev V., Orlova A. Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists MaSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer. Pharmaceutics. 2021;13:182.
18. Bragina O., Chernov V., Schulga А., Konovalova E., Garbukov E., Vorobyeva A., Orlova A., Tashireva L., Sörensen J., Zelchan R., Medvedeva A., Deyev S., Tolmachev V. Phase I Trial of 99mTc-(HE)3-G3 a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer. J Nucl Med. 2022;63:528-535.
19. Schroeder R., de Visser M., van Weerden W.M. Androgen-Regulated Gastrin-Releasing Peptide Receptor Expression in Androgen-Dependent Human Prostate Tumor Xenografts. Int J Cancer. 2010;126;12:2826–2834. doi: 10.1002/ijc.25000.
20. Брагина О.Д., Чернов В.И., Ларькина М.С., Зельчан Р.В., Синилкин И.Г., Медведева А.А. Простатический специфический мембранный антиген: современные возможности в диагностике рака предстательной железы // Молекулярная медицина. 2018. Т.16. №4. С. 3-8 [Bragina O.D., Chernov V.I., Lar’kina M.S., Zel’chan R.V., Sinilkin I.G., Medvedeva A.A. Prostate-Specific Membrane Antigen: Modern Possibilities in the Diagnosis of Prostate Cancer. Molekulyarnaya Meditsina = Molecular Medicine. 2018;16;4:3-8 (In Russ.)].
21. Медведева А.А., Чернов В.И., Усынин Е.А., Зельчан Р.В., Брагина О.Д., Лушникова Н.А. Использование 177Lu-ПСМА для радионуклидной терапии у пациентов с кастрационно-резистентным раком предстательной железы // Сибирский онкологический журнал. 2021. Т.20. №3. С. 115-123 [Medvedeva A.A., Chernov V.I., Usynin Ye.A., Zel’chan R.V., Bragina O.D., Lushnikova N.A. Use of 177Lu-PSMA for Radionuclide Therapy in Patients with Castration-Resistant Prostate Cancer. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2021;20;3:115-123 (In Russ.)]. doi: 10.21294/1814-4861-2021-20-3-115-123
22. Вязьмин В.В., Зуков Р.А., Чанчикова Н.Г., Левченко Е.А., Чернов В.И. Современные возможности ПЭТ/КТ в диагностике рака предстательной железы // Сибирский онкологический журнал. 2021. Т.20. №5. С. 115-122 [Vyaz’min V.V., Zukov R.A., Chanchikova N.G., Levchenko Ye.A., Chernov V.I. Modern Capabilities of PET/CT in the Diagnosis of Prostate Cancer. Sibirskiy Onkologicheskiy Zhurnal = Siberian Oncology Journal. 2021;20;5:115-122 (In Russ.)].
23. Bertacinni G., Impicciatore M., Molina E., Zappia L. Action of Bombesin on Human Gastrointestinal Motility. Italian J Gastroent. 1974;6:45–51.
24. Stoykow C., Erbes T., Maecke H.R., Bulla S., Bartholomä M., Mayer S., Drendel V., Bronsert P., Werner M., Gitsch G., Weber W.A., Stickeler E., Meyer P.T. Gastrin-Releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist 68Ga-RM2 And PET. Theranostics. 2016;6:1641-1650.
25. Wieser G., Mansi R., Grosu A.L., Schultze-Seemann W., Dumont-Walter R.A., Meyer P.T., Maecke H.R., Reubi J.C., Weber W.A. Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist – from Mice to Men. Theranostics. 2014;4:412-419.
26. Kwee S.A., Wei H., Sesterhenn I., Yun D., Coel M.N. Localization of Primary Prostate Cancer with Dual-Phase 18F-Fluorocholine PET. J Nucl Med. 2006;47:262-269.
27. Van de Wiele C., Dumont F., Dierckx R.A., Peers S.H., Thornback J.R., Slegers G., Thierens H. Biodistribution and Dosimetry of 99mTc-RP527 a Gastrin-Releasing Peptide (GRP) Agonist for the Visualization of GRP Receptor–Expressing Malignancies. J Nucl Med. 2001;42:1722–1727.
28. Mather S.J., Nock B.A., Maina T., Gibson V., Ellison D., Murray I., Sobnack R., Colebrook S., Wan S., Halberrt C., Szysko T., Powles T., Avril N. GRP Receptor Imaging of Prostate Cancer Using [99mTc]Demobesin 4: a First-in-Man Study. Mol Imaging Biol. 2014;16:888-895.
29. Bakker I.L., Fröberg A.C., Busstra M.B., Verzijlbergen J.F., Konijnenberg M., van Leenders G.H., Schoots I.G., de Blois E., van Weerden W.M., Dalm S.U., Maina T., Nock B.A., de Jong M. GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients. J Nucl Med. 2021;62:1517–1523.
30. Zhang J., Niu G., Fan X., Lang L., Hou G., Chen L., Wu H., Zhu Z., Li F., Chen X. PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. J Nucl Med. 2018;59:922–928.
31. den Wyngaert T.V., Elvas F., De Schepper S., Kennedy J.A., Israel O. SPECT/CT: Standing on the Shoulders of Giants. It is Time to Reach for the Sky! J Nucl Med. 2020;61:1284–1291.
32. Chernov V., Rybina A., Zelchan R., Medvedeva A., Bragina O., Lushnikova N., Doroshenko A., Usynin E., Tashirevа L., Vtorushin S., Abouzayed A., Rinne S.S., Sörensen J., Tolmachev V., Orlova A. Phase I Trial of [99m Tc]Tc-maSSS-PEG2 -RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors. Cancers. 2023;15:1631. doi: 10.3390/cancers15061631.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. With the support of the Strategic Academic Leadership program ‟Priority 2030” No. 2030-FROM-024-202–2024 ‟Radionuclide theranostics of prostate cancer”.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.10.2024. Accepted for publication: 25.11.2024.